Cognitive Neurology Unit Clinical Registry
About this study
A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease
- Condition
- Alzheimer Disease
- Tested
- Lecanemab
- Sponsor
- Beth Israel Deaconess Medical Center
Who can join
- Age
- 50 to 95 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 13
- Minimum age: 50 years
- Maximum age: 95 years
- Study condition: Alzheimer Disease
- o Patient meets clinical criteria for mild cognitive impairment or early dementia from Alzheimer's disease
- Patient has evidence of cognitive impairment on neuropsychological testing
- Patient has not progressed to the moderate stage of dementia based on neuropsychological testing or clinical judgement
- Amyloid PET imaging and/or CSF analysis consistent with Alzheimer's disease
- Amyloid PET imaging positive
- CSF p-Tau/Abeta42 ration \>0.023 and ABeta42 \< 1027\*\*
- 3T MRI in past 6 months
- Patient has a care partner
- Patient under the care of an appropriate BI-Lahey amyloid clinic
- Patient is on a stable medication regimen
Exclusion 9
- o Recent stroke or suspected TIA in the past year
- Pregnancy
- Active autoimmune or immunological disease
- Systemic treatment with immunosuppressants, immunoglobulins, or monoclonal antibodies or their derivatives
- Bleeding disorder with Plts \< 50,000 or INR \> 1.5
- On warfarin, heparin, or DOAC
- On dual antiplatelet therapy
- Non Alzheimer disease cause of dementia/MCI
- ApoE e4 homozygote
Where
1 site, 1 recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Contact
-
Dan Z Press, MD
(617) 667-4074 dpress@bidmc.harvard.edu
-
Chun Lim, MD
(617) 667-4074 clim@bidmc.harvard.edu
Potential match only. Final eligibility is determined by the study team.